Actively Recruiting
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges
Led by Dr. George Luciuk · Updated on 2026-02-05
100
Participants Needed
1
Research Sites
44 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and/or drug) or oral immunotherapy (OIT).
CONDITIONS
Official Title
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females aged 12 years or older with known or suspected allergen sensitivity, including documented IgE-mediated allergy
- Have undergone allergy testing, a planned oral challenge or oral immunotherapy, or subcutaneous immunotherapy and experienced a Grade 2 or higher systemic allergic reaction
- For females of child-bearing potential, not pregnant or lactating and willing to use acceptable contraception between screening and end of study
You will not qualify if you...
- Known allergy or sensitivity to epinephrine or ingredients of inhaled epinephrine
- Presence of any clinical disease or condition that could affect study results or increase risk as judged by the investigator
- Abnormal vital signs at screening: systolic BP < 90 or > 140 mmHg, diastolic BP < 40 or > 90 mmHg, heart rate < 45 or > 100 bpm, respiration rate < 8 or > 20 per minute
- Pregnant, planning pregnancy, or lactating females
- Participation in another investigational drug or biologic study within 30 to 60 days before screening or during this study
- Previous treatment in this study
- Any other reason deemed by the investigator to affect risk-benefit, study results, or compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kokua Pharma Inc.
Richmond, British Columbia, Canada, V7C 5L9
Actively Recruiting
Research Team
G
George H. Luciuk, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here